Your browser doesn't support javascript.
loading
Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.
Girotti, Maria Romina; Gremel, Gabriela; Lee, Rebecca; Galvani, Elena; Rothwell, Dominic; Viros, Amaya; Mandal, Amit Kumar; Lim, Kok Haw Jonathan; Saturno, Grazia; Furney, Simon J; Baenke, Franziska; Pedersen, Malin; Rogan, Jane; Swan, Jacqueline; Smith, Matthew; Fusi, Alberto; Oudit, Deemesh; Dhomen, Nathalie; Brady, Ged; Lorigan, Paul; Dive, Caroline; Marais, Richard.
Afiliación
  • Girotti MR; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom.
  • Gremel G; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom.
  • Lee R; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom.
  • Galvani E; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom.
  • Rothwell D; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom.
  • Viros A; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom.
  • Mandal AK; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom.
  • Lim KH; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom.
  • Saturno G; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom.
  • Furney SJ; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom.
  • Baenke F; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom.
  • Pedersen M; Targeted Therapy Team, The Institute of Cancer Research, London, United Kingdom.
  • Rogan J; The University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Swan J; Research Services, Cancer Research UK Manchester Institute, Manchester, United Kingdom.
  • Smith M; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom.
  • Fusi A; The University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Oudit D; The University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Dhomen N; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom.
  • Brady G; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom.
  • Lorigan P; The University of Manchester, The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Dive C; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom.
  • Marais R; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom. richard.marais@cruk.manchester.ac.uk.
Cancer Discov ; 6(3): 286-99, 2016 Mar.
Article en En | MEDLINE | ID: mdl-26715644
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Medicina de Precisión / Melanoma Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Discov Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Medicina de Precisión / Melanoma Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Discov Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido